Therapeutic uses of dulaglutide
AssigneeEli Lilly and Company
InventorsJeffrey S. Riesmeyer, David Bradley Woodward
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.
Claims8
A method of reducing the risk of non-fatal stroke in a patient with type 2 diabetes mellitus comprising administering a therapeutically effective amount of dulaglutide to the patient once weekly, wherein the patient has type 2 diabetes mellitus and either:
- (a) multiple cardiovascular risk factor without established disease;
- or (b) established cardiovascular disease;
- and wherein the method reduces the risk of non-fatal stroke by at least about 10%.
Dependencies are inferred from the claim text.